High Prevalence of Metformin-Associated Vitamin B12 Deficiency Among Type 2 Diabetic Patients in Libya: A Cross-Sectional Study
Abstract
Metformin is a drug regularly used to treat type 2 diabetic patients by controlling blood glucose concentration. It is heavily linked to vitamin B12 deficiency. While this association has been thoroughly studied in Western demographics, Libyan data are lacking. Genetic, dietary, and environmental factors may result in different results than those found in other cohorts.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.